2126 — JW (Cayman) Therapeutics Co Cashflow Statement
0.000.00%
Last trade - 00:00- HK$712.70m
- -HK$30.71m
- CNY173.86m
- 19
- 32
- 24
- 10
Annual cashflow statement for JW (Cayman) Therapeutics Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -633 | -1,664 | -702 | -846 | — |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 444 | 1,359 | 34.8 | 231 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -17.1 | 20.1 | 58.1 | -9.12 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -189 | -261 | -561 | -537 | — |
| Capital Expenditures | -114 | -130 | -137 | -101 | — |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -3.49 | 38.3 | 0 | -23.5 | — |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -118 | -91.9 | -137 | -124 | — |
| Financing Cash Flow Items | 34.7 | -27.3 | -18.3 | -6.79 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 414 | 2,859 | -30.6 | 112 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 121 | 2,376 | -796 | -451 | — |